New state program for development of Russia's pharma industry
The Russian government has officially presented a new state program for the development of the domestic pharmaceutical industry for the next 10 years - "Pharma-2030," reports The Pharma Letter’s local correspondent.
As part of the strategy, the development of innovative drugs will be the main task of Russian drugmakers until 2030, while the state government, from its side, will focus on the simplification of regulation in the industry, will increase state subsidies and provide additional preferential tax regimes for domestic drugmakers and foreign companies, operating in the domestic market.
According to Vasily Osmakov, Deputy Head of the Ministry of Industry and Trade, Pharma-2030 should allow the Russian pharmaceutical industry to move to a new stage of development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze